CD33 and acute myeloid leukemia: The clinical trial evaluating the safety and efficacy of anti-CD33 (ADC SGN-CD33A) in newly diagnosed AML patients (NCT02326584) demonstrated that ADC SGN-CD33A is safe both as a monotherapy and in combination with standard high-dose cytarabine (HiDAC) therapy.